Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways: With the drug still…
Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
The Chinese biotech is developing a weight-loss drug in a tablet form that could challenge leading products in the booming anti-obesity market Key Takeaways: The AstraZeneca licensing deal in 2023…
Hengrui Pharma targets obesity drug launch after test success
The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trials Key Takeaways: Participants receiving…
AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
Recent Articles
RELATED ARTICLES
-
Hengrui Pharma targets obesity drug launch after test success
1278.HK600276.SHG
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
- Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
-
Medtide launches IPO to bulk up its weight-loss business
3880.HK
-
Fosun’s Portuguese makeover moves ahead with $360 million health disposal
0656.HK
-
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
